- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of PD-L1 expression in the tumor microenvironment
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-08
DOI
10.1186/s13045-020-01027-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma
- (2020) Zhuochao Liu et al. Aging-US
- Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
- (2020) Haifang Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells
- (2020) Yihe Yan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epstein–Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas
- (2020) Chan Jin Yoon et al. Gastric Cancer
- Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma
- (2020) Tianyu Zhu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The role of cancer-derived microRNAs in cancer immune escape
- (2020) Ming Yi et al. Journal of Hematology & Oncology
- Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
- (2020) Yehui Shi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Angiotensin II contributes to intratumoral immunosuppression via induction of PD-L1 expression in non-small cell lung carcinoma
- (2020) Kaiyong Yang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Endoplasmic reticulum stress‐induced exosomal miR‐27a‐3p promotes immune escape in breast cancer via regulating PD‐L1 expression in macrophages
- (2020) Xiaoli Yao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
- (2020) Wenjie Zhang et al. Journal for ImmunoTherapy of Cancer
- NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
- (2020) Tung-Yung Huang et al. Cells
- Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- (2020) Leïla Sarah Sellam et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
- (2020) Jimin Yuan et al. Journal of Hematology & Oncology
- Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer
- (2019) Young-Bae Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
- (2019) Lanlan Gao et al. EBioMedicine
- Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
- (2019) Yu Pan et al. OncoImmunology
- Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
- (2019) Cecilia Roux et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
- (2019) Jonathan B Lamano et al. CLINICAL CANCER RESEARCH
- Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression
- (2019) Wei Wang et al. CANCER RESEARCH
- Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
- (2019) Han Yao et al. Nature Biomedical Engineering
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
- (2019) Mingjing Shen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
- (2019) Thijs S Stutvoet et al. JOURNAL OF PATHOLOGY
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
- (2019) Abdullah Al Emran et al. TRENDS IN IMMUNOLOGY
- IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
- (2019) Li-Chuan Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Activation of a protumorigenic IFNγ/STAT1/IRF-1 signaling pathway in keratinocytes following exposure to solar ultraviolet light
- (2019) Nicholas Blazanin et al. MOLECULAR CARCINOGENESIS
- MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function
- (2019) Hyun Kyung Ahn et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
- (2019) Jing Shen et al. MODERN PATHOLOGY
- Crosstalk of intracellular post-translational modifications in cancer
- (2019) Zheng Wu et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
- (2019) Xiaojuan Shi et al. Journal of Hematology & Oncology
- EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
- (2019) Shunli Peng et al. Molecular Cancer
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma
- (2019) Dan Xu et al. OncoTargets and Therapy
- EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
- (2019) Gang Xiao et al. Journal for ImmunoTherapy of Cancer
- MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
- (2019) Jing-Ran Sun et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Cisplatin‐mediated down‐regulation of miR‐145 contributes to up‐regulation of PD‐L1 via the c‐Myc transcription factor in cisplatin‐resistant ovarian carcinoma cells
- (2019) Q. Sheng et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
- (2018) Wei-Bin Xie et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
- (2018) Meixuan Chen et al. Clinical Breast Cancer
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
- (2018) Dongfang Tang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Gut microbiome modulates efficacy of immune checkpoint inhibitors
- (2018) Ming Yi et al. Journal of Hematology & Oncology
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR -Mutant Patients
- (2018) Marina Chiara Garassino et al. Journal of Thoracic Oncology
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
- (2018) Eleni Anastasiadou et al. LEUKEMIA
- PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
- (2018) Nahal Haddadi et al. Molecular Cancer
- MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
- (2018) Jiahuan Zou et al. MOLECULAR IMMUNOLOGY
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
- (2018) LiJun Xu et al. Molecular Oncology
- Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer
- (2018) Peixin Dong et al. ONCOGENE
- Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
- (2018) Ioannis Zerdes et al. ONCOGENE
- Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion
- (2018) Cheng Sun et al. Nature Communications
- STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
- (2018) Jung-Mao Hsu et al. Nature Communications
- Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
- (2018) Maher Albitar et al. Oncotarget
- PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
- (2018) A. Asgarova et al. OncoImmunology
- Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects
- (2018) Lingtong Meng et al. ACS Nano
- Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
- (2018) Tammy Linlin Song et al. BLOOD
- LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation
- (2018) Hui Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma
- (2018) Fajun Qu et al. JOURNAL OF DRUG TARGETING
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Palmitoylation stabilizes PD-L1 to promote breast tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
- (2018) Goran Micevic et al. Pigment Cell & Melanoma Research
- Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages
- (2017) Canhua Jiang et al. IMMUNOBIOLOGY
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
- (2017) Xun Wang et al. IMMUNOLOGY LETTERS
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- MYC expression correlates with PD-L1 expression in non-small cell lung cancer
- (2017) Eun Young Kim et al. LUNG CANCER
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
- (2017) A Bouillez et al. ONCOGENE
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
- (2017) Ming Jing Shen et al. Oncotarget
- EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
- (2017) Koung Jin Suh et al. Oncotarget
- A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
- (2017) Paolo D'Arrigo et al. Oncotarget
- PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
- (2017) Alina Franzen et al. Oncotarget
- Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
- (2017) Christina Demuth et al. Oncotarget
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
- (2017) Justin M. David et al. OncoImmunology
- IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
- (2017) Ji Wook Moon et al. Scientific Reports
- Is H3K4me3 instructive for transcription activation?
- (2016) Françoise S. Howe et al. BIOESSAYS
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
- (2016) Julie George et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer
- (2016) Seiichi Ikeda et al. Journal of Thoracic Oncology
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
- (2016) Diane Goltz et al. OncoImmunology
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
- (2015) Xi Wang et al. CELLULAR SIGNALLING
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- The interplay of histone modifications - writers that read
- (2015) T. Zhang et al. EMBO REPORTS
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-27 induces the expression of IDO and PD-L1 in human cancer cells
- (2015) Grazia Carbotti et al. Oncotarget
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
- (2014) David D. W. Twa et al. BLOOD
- Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
- (2014) Kousaku Mimura et al. CANCER SCIENCE
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
- (2014) Dagmar Quandt et al. Journal of Translational Medicine
- Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection
- (2014) S Yao et al. Mucosal Immunology
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Ubiquitination and selective autophagy
- (2012) S Shaid et al. CELL DEATH AND DIFFERENTIATION
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation
- (2012) XIAO YAN NI et al. ONCOLOGY REPORTS
- TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus
- (2012) Jing-Ni Ou et al. Scientific Reports
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started